[Federal Register Volume 66, Number 57 (Friday, March 23, 2001)]
[Notices]
[Page 16188]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-7262]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Availability for Non-Exclusvie, Exclusive, or Partially Exclusvie 
Licensing of U.S. Patent Application Concerning Use of Antibodies to 
Sialidase as Anti-Infectious Agents and Anti-Inflammatory Agents

AGENCY: U.S. Army Medical Research and Materiel Command, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the 
availability for licensing of U.S. Patent No. 6,066,323 entitled ``Use 
of Antibodies to Sialidase as Anti-infectious Agents and Anti-
Inflammatory Agents'' issued May 23, 2000. This patent application has 
been assigned to the United States Government as represented by the 
Secretary of the Army.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, Maryland 21702-5012

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research & Technology Assessment, (301) 619-6664. Both 
telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: Sialic acids have the ability to prevent 
hyposialylation of cells as competitive inhibitors of endogenous 
sialidse. It is now also possible to develop antibodies to mammalian 
sialidase that significantly reduce influx of neutrophils into 
inflammatory sites.

Gregory D. Showalter,
Army Federal Register Liaison Officer.
[FR Doc. 01-7262 Filed 3-22-01; 8:45 am]
BILLING CODE 3770-08-M